196 related articles for article (PubMed ID: 20181986)
1. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Krumholz HM
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986
[No Abstract] [Full Text] [Related]
2. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH
Circulation; 2010 Apr; 121(16):1868-77. PubMed ID: 20179252
[No Abstract] [Full Text] [Related]
3. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ;
J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044
[No Abstract] [Full Text] [Related]
4. [The effects of thiazolidinedione from the cardiologic viewpoint].
Ziegler R
Med Monatsschr Pharm; 2005 Oct; 28(10):365. PubMed ID: 16245456
[No Abstract] [Full Text] [Related]
5. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
[No Abstract] [Full Text] [Related]
6. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
7. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
9. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
10. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
11. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
12. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
Krantz MJ
Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
[No Abstract] [Full Text] [Related]
13. [Heart failure with thiazolidinedione treatment: what do we know today?].
Erdmann E
Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas PC; Sarafidis PA; Lasaridis AN
J Cardiometab Syndr; 2007; 2(4):295-6. PubMed ID: 18059214
[No Abstract] [Full Text] [Related]
15. Cardiovascular risk and TZD: safe therapy for the elderly?
Burt R; Townsend S; Armor B
Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
[TBL] [Abstract][Full Text] [Related]
16. [What about the controversy regarding rosiglitazone].
Scheen AJ; De Flines J; Paquot N
Rev Med Liege; 2007 Sep; 62(9):560-5. PubMed ID: 17966792
[TBL] [Abstract][Full Text] [Related]
17. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
18. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
Schernthaner G; Currie CJ; Schernthaner GH
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S155-61. PubMed ID: 23882041
[No Abstract] [Full Text] [Related]
19. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
20. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
Håkansson J
Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
